Ikena Oncology
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Ikena Oncology (NASDAQ: IKNA) was a Boston biotechnology company developing targeted cancer therapies. Its pipeline included IK-930, a TEAD1-selective Hippo pathway inhibitor, and IK-595, a novel MEK-RAF molecular glue for RAS and RAF mutant cancers. It had raised about $209 million.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- IK-930 discontinued; layoffs
On May 28, 2024, Ikena discontinued its lead program IK-930 after disappointing Phase 1 data, cut about 53% of its workforce, and said it was evaluating strategic options; Bristol Myers Squibb had walked away from a collaboration earlier in the year.
- Merger with Inmagene
In October 2024 Ikena announced a merger with privately held immunology company Inmagene Biopharmaceuticals; the combined company operates under the InmageneBio name on Nasdaq as 'IMA', focused on the OX40 antibody IMG-007 for atopic dermatitis.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.